Demonstration article

This sample was written to show how Northstar Briefing presents journalism. It does not report real events and contains no real quotations, data or named sources.

It surprises many people that an identical pill, made in the same factory, can carry very different prices in different countries. The explanation lies in the unusual economics of pharmaceuticals, where the cost of making an extra dose is often small but the cost of discovering and testing a new medicine is very large.

Research costs and patents

Developing a medicine involves years of laboratory work and clinical trials, many of which fail. Patents grant the successful developer a period of exclusive sales to recover those costs. During that period, the price is set less by the cost of production than by what each market will bear — and markets differ widely in what that is.

The role of the buyer

Where a single national health system buys medicines for an entire population, it has considerable bargaining power. It can decline to fund a drug it judges poor value, and manufacturers know that. Where purchasing is fragmented among many insurers and providers, each buyer has less leverage, and prices tend to be higher.

A medicine's price is less a fact about chemistry than a fact about who is negotiating.

Many governments also use reference pricing, setting what they pay by looking at prices in comparable countries. This links markets together in ways that shape company strategy. Manufacturers may delay launching in lower-priced markets, or negotiate confidential discounts, to avoid lowering the reference price elsewhere.

Factors that shape medicine prices

Patent protection and the presence of generic competitors

Whether buying is centralised or fragmented

Health technology assessment and willingness to say no

Reference pricing linked to other countries

Confidential rebates that make list prices misleading

The debate over fairness is genuine. Some argue that countries paying lower prices are benefiting from research funded by those paying more. Others reply that high prices reflect weak bargaining rather than a necessary reward for innovation, and that public funding of basic science already contributes a great deal. Both views contain some truth.

Once patents expire, the picture changes sharply. Generic manufacturers can enter, competition pushes prices toward the cost of production, and differences between countries tend to narrow. The most contested period is therefore the years of exclusivity, when policy choices — not manufacturing costs — determine what patients and taxpayers pay.

For patients, these dynamics are mostly invisible. What they experience is whether a medicine is available, how long it takes to arrive and how much they pay at the pharmacy counter. Those outcomes depend on choices made far upstream, in negotiations and regulatory reviews that rarely receive public attention but shape access to treatment as much as any scientific advance.